Skip to main content

Ortho-Clinical Kills Alzheimer s License with SynX

NEW YORK, March 5 (GenomeWeb News) - Ortho-Clinical Diagnostics has ended an exclusive agreement to license certain Alzheimer's diagnostics technology from SynX Pharma, and has stopped trying to develop the technology, SynX said today.


As a result, Toronto-based SynX has re-acquired from Ortho the worldwide rights to the technology, the company said.


SynX won a USpatent for the technology in September 2002, and licensed it exclusively to Ortho one month later. SynX  said it plans to "pick up where Ortho has left off" and continue developing the Alzheimer's technology. The company will begin seeking non-exclusive licensing partners and consider plans to add it to its Nexus Dx point-of-care product line.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.